Article
The Irreversible FGFR Inhibitor KIN-3248 Overcomes FGFR2 Kinase Domain Mutations.
Clinical cancer research : an official journal of the American Association for Cancer Research - 15 May 2024
Balasooriya Eranga R, Wu Qibiao, Ellis Haley, Zhen Yuanli, Norden Bryanna L, Corcoran Ryan B, Mohan Adithi, Martin Eric, Franovic Aleksandra, Tyhonas John, Lardy Matthew, Grandinetti Kathryn B, Pelham Robert, Soroceanu Liliana, Silveira Vanessa S, Bardeesy Nabeel
Abstract excerpt
PURPOSE: FGFR2 and FGFR3 show oncogenic activation in many cancer types, often through chromosomal fusion or extracellular domain mutation. FGFR2 and FGFR3 alterations are most prevalent in intrahepatic cholangiocarcinoma (ICC) and bladder cancers, respectively, and multiple selective reversible and covalent pan-FGFR tyrosine kinase inhibitors (TKI) have been approved in these contexts. However, resistance, often...
Topics
Join the communities discussing this publication.